Warsaw-based Zimmer Biomet Holdings Inc. (NYSE: ZBH) has received clearance from the U.S. Food and Drug Administration for its ROSA Partial Knee System. The medical device manufacturer says the system will be used for robotically-assisted partial knee replacement surgeries.
The system is part of Zimmer Biomet’s ROSA Robotics platform, which also includes devices for total knee replacement surgeries, as well as neurosurgical and spine procedures.
“The FDA clearance of the ROSA Partial Knee System just two years after the introduction of the ROSA Total Knee System builds on the success of our ROSA robotics portfolio, which is designed to help enhance surgical accuracy, precision and efficiency, through the use of intraoperative data that can personalize each procedure,” Ivan Tornos, chief operating officer for Zimmer Biomet, said in a news release. “As a result, the ROSA Partial Knee System empowers patients to truly get the knee that’s the best fit for their needs.”
Zimmer Biomet says the system uses proprietary imaging technology and real-time, intraoperative data collection on a patient’s soft tissue and bone anatomy to help improve flexion and restoration of natural joint movement in the knee.